GH Secretagogue Guide: Which One to Pick
Ipamorelin, sermorelin, CJC-1295, GHRP-6, and MK-677 compared by pulsatility, cortisol/prolactin effects, route, and goal to guide agent selection.
Growth Hormone Secretagogues: Drug Class Monograph
7 source-based articles maintained by the HealthRX.com Editorial Team.
7articles
3topic areas covered
Jan 20, 2025latest review
Growth Hormone Secretagogues: Drug Class Monograph library
Showing 7 of 7 clinical reviews.
GH Secretagogue Side Effects: Edema, Paresthesia, Insulin Risk
Edema, paresthesia, and insulin resistance risk vary by age, sex, and comorbidity with GH secretagogues; see population-specific dosing and monitoring guidance.
GH Secretagogues Adverse-Event Management Protocols
A prescriber-level guide to identifying, grading, and managing adverse events associated with GH secretagogue therapy, including ipamorelin, sermorelin, CJC-1295, and MK-677. Covers mechanism-based toxicity, monitoring schedules, and dose-adjustment algorithms.
GH Secretagogues Billing & Prior-Auth Playbook
A prescriber-level guide to growth hormone secretagogue drug classes, coding strategy, prior-authorization tactics, and compounding compliance for ipamorelin, sermorelin, tesamorelin, and MK-677.
GH Secretagogues Drug-Drug Interaction Table
Complete drug-drug interaction (DDI) reference for growth hormone secretagogues including ipamorelin, CJC-1295, tesamorelin, sermorelin, and MK-677. Written for prescribers and pharmacists.
GH Secretagogues Monitoring Bundle: A Complete Prescriber Reference
A physician-level guide to monitoring patients on GH secretagogues (ipamorelin, CJC-1295, MK-677, GHRP-2, GHRP-6). Covers baseline labs, on-therapy intervals, dose titration, safety signals, and discontinuation criteria with primary-source citations.
GH Secretagogues Titration & Tapering Algorithms
A prescriber-oriented overview of how growth hormone secretagogues (ipamorelin, CJC-1295, sermorelin, MK-677) are typically titrated and tapered in compounding practice, with monitoring checkpoints and the boundary between general protocol patterns and individualized prescribing.